Eagle Pharmaceuticals, Inc.
EGRX
EGRX was delisted on the 2nd of October, 2024.
153 hedge funds and large institutions have $334M invested in Eagle Pharmaceuticals, Inc. in 2023 Q1 according to their latest regulatory filings, with 21 funds opening new positions, 53 increasing their positions, 63 reducing their positions, and 19 closing their positions.
109% more call options, than puts
Call options by funds: $48K | Put options by funds: $23K
11% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 19
2% more capital invested
Capital invested by funds: $328M → $334M (+$6.59M)
1% more funds holding
Funds holding: 152 → 153 (+1)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
16% less repeat investments, than reductions
Existing positions increased: 53 | Existing positions reduced: 63
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of America
Charlotte,
North Carolina
|
+$8.23M |
| 2 |
Millennium Management
New York
|
+$6.17M |
| 3 |
AQR Capital Management
Greenwich,
Connecticut
|
+$3.86M |
| 4 |
BIP
Brandes Investment Partners
La Jolla,
California
|
+$3.83M |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
+$3.23M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
-$16.3M |
| 2 |
Bank of Nova Scotia
Toronto,
Ontario, Canada
|
-$2.49M |
| 3 |
Janus Henderson Group
London,
United Kingdom
|
-$2.42M |
| 4 |
ETM
Euclidean Technologies Management
Seattle,
Washington
|
-$2.11M |
| 5 |
DZ Bank
Frankfurt Am Main,
Germany
|
-$1.89M |
EGRX Hedge Fund Activity: Q1 2023 in Review
153 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Eagle Pharmaceuticals, Inc. (EGRX) for Q1 2023, worth a combined $334M — up 2% from $328M a quarter earlier.
Buyers outnumbered sellers: 21 funds opened new EGRX positions and 19 closed out — a net gain of 2 holders — while 53 added to existing stakes and 63 trimmed.
The largest buyer was Bank of America, adding an estimated $8.23M. The largest seller was State Street, cutting an estimated $16.3M.
- 153 institutional investors held Eagle Pharmaceuticals, Inc. (EGRX) as of Q1 2023, up from 152 in Q4 2022.
- Funds reported $334M of Eagle Pharmaceuticals, Inc. stock for Q1 2023, up 2% quarter-over-quarter.
- 21 funds opened new Eagle Pharmaceuticals, Inc. positions in Q1 2023 and 19 closed out, a net change of +2 holders.
- The largest Eagle Pharmaceuticals, Inc. buyer in Q1 2023 was Bank of America, an estimated $8.23M added.
- The largest Eagle Pharmaceuticals, Inc. seller in Q1 2023 was State Street, an estimated $16.3M sold.
Based on aggregated 13F filings for Q1 2023.